Market Access
Dealing with Insurers’ Copay Accumulators
Over the past couple of years, more and more insurers have started to implement ...
The Scrutiny on Rebates and Prices Will Change the Pharma-Payer Relationship
The government is the largest payer in the U.S. through Medicare and Medicaid, and ...
Four Key Questions About Payer Strategies in 2019
PM360 asked those with expertise in payer strategies how changes are impacting pharma’s relationship ...
From Capitol Hill to the Oval Office: What Washington Has in Store for Pharma and Healthcare Communications in 2019
With 71% of voters citing it as their foremost concern, healthcare was among the ...
Healthcare’s Financial Literacy Gap
A 2016 Harris Poll survey offered this shocking insight: The number of people who ...
Engagement Strategy with IHS & IDNs
Clinical pathways are formalized processes of care designed to reduce treatment variability. They can ...
Psoriasis Treatment: Unmet Needs Present 2019 Opportunities
Psoriasis and related conditions represent as an evolving treatment domain for many pharmas—and obvious ...
Learning to Speak HEOR
As one formulary decision-maker told us: “Recent regulation guidance on FDAMA114 frees up pharma ...
Healthcare Midterm Election Results: A Marketing Toss Up
With the 2018 midterm elections in the rearview mirror, the business of healthcare continues ...
California Will Require Pharma to Explain Rationale Behind Price Hikes in 2019
As President Trump continues to make promises to lower drug prices, the state of ...
Preparing for Possible Changes to Medicare Part D
Even prior to the midterm elections, the Trump administration has been proposing several changes ...
Is Step Therapy Now a Possibility for Part B Drugs?
The Trump administration’s drug cost blueprint looked at the possibility of moving Part B ...
Seize the Day
The multiple forces dramatically reshaping the healthcare industry show no sign of abating. Influence ...